Wall Street Zen lowered shares of Disc Medicine (NASDAQ:IRON – Free Report) from a hold rating to a sell rating in a research report report published on Saturday,Wall Street Zen reports.
A number of other equities analysts have also issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a research report on Friday, July 17th. Wedbush reissued an “outperform” rating and issued a $88.00 price target on shares of Disc Medicine in a report on Wednesday, June 10th. HC Wainwright raised their price target on shares of Disc Medicine from $118.00 to $120.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Finally, Morgan Stanley restated an “overweight” rating and set a $90.00 price objective on shares of Disc Medicine in a report on Monday, August 17th. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $106.50.
Read Our Latest Stock Analysis on IRON
Disc Medicine Stock Performance
Disc Medicine (NASDAQ:IRON – Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($1.54) EPS for the quarter, topping analysts’ consensus estimates of ($1.71) by $0.17. On average, equities analysts forecast that Disc Medicine will post -6.61 earnings per share for the current year.
Insider Transactions at Disc Medicine
In related news, insider Rahul Khara sold 5,000 shares of the company’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $80.00, for a total value of $400,000.00. Following the completion of the transaction, the insider directly owned 52,324 shares in the company, valued at approximately $4,185,920. This represents a 8.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Jonathan Yen-Wen Yu sold 8,796 shares of the firm’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $83.12, for a total value of $731,123.52. Following the completion of the transaction, the chief operating officer directly owned 54,324 shares of the company’s stock, valued at approximately $4,515,410.88. This trade represents a 13.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 153,612 shares of company stock valued at $11,431,811. 3.76% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Disc Medicine
Several institutional investors and hedge funds have recently bought and sold shares of the business. California State Teachers Retirement System raised its stake in shares of Disc Medicine by 8,273.0% in the 2nd quarter. California State Teachers Retirement System now owns 2,878,790 shares of the company’s stock valued at $210,555,000 after buying an additional 2,844,408 shares in the last quarter. AXQ Capital LP acquired a new stake in shares of Disc Medicine during the 2nd quarter valued at about $441,000. Nykredit A S acquired a new stake in shares of Disc Medicine during the 2nd quarter valued at about $103,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Disc Medicine by 2.9% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 114,109 shares of the company’s stock valued at $8,346,000 after acquiring an additional 3,219 shares during the period. Finally, Wellington Management Group LLP increased its stake in Disc Medicine by 0.3% in the second quarter. Wellington Management Group LLP now owns 1,741,351 shares of the company’s stock valued at $127,362,000 after acquiring an additional 5,975 shares during the period. Institutional investors own 83.70% of the company’s stock.
About Disc Medicine
Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.
The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.
Read More
- Five stocks we like better than Disc Medicine
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for Disc Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Disc Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
-limited-logo.jpg){kind=logo}
